epithalon vs ss-31
epithalon (C-tier) vs ss-31 (A-tier). mechanism, trials, claims vs data, dosing literature. side-by-side reference.
epithalon — tier C
russian longevity peptide. one lab. one cohort. the lifespan claims have never been replicated.
Russian longevity peptide. one lab (Khavinson). one human cohort (2003). the lifespan claims have never been replicated.
Russia Khavinson '80s · half-life minutes in plasma; downstream effects on melatonin signaling persist longer · focus
ss-31 — tier A
the first mitochondria-targeted peptide drug. FDA-approved september 2025. for Barth syndrome, studied for heart failure.
the first FDA-approved peptide drug that targets mitochondria. Forzinity for Barth syndrome, ~$800,000 a year.
FDA '25 elamipretide · Barth syndrome · half-life 3-4 hours in circulation; functional effects persist 12-16 hours due to mitochondrial retention · healing
at a glance
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.